참고문헌
- Acevedo F, Herrera ME, Madrid J, Sanchez C (2013). Neoadyuvant endocrine therapy in breast cancer. Revista Medica de Chile, 141, 367-74. https://doi.org/10.4067/S0034-98872013000300013
- Berry DA, Cronin KA, Plevritis SK, et al (2005). Effect of screening and adjuvant therapy on mortality from breast cancer. New Engl J Med, 353, 1784-92. https://doi.org/10.1056/NEJMoa050518
- Burstein HJ, Piccart-Gebhart MJ, Perez EA (2012). Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines? J Clin Oncol, 30, 2179-82. https://doi.org/10.1200/JCO.2012.42.0695
- Cuzick J, Dowsett M, Pineda S, et al (2011). Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. J Clin Oncol, 29, 4273-78. https://doi.org/10.1200/JCO.2010.31.2835
- De Azambuja E, Cardoso F, De Castro G Jr (2007). Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer, 96, 1504-13. https://doi.org/10.1038/sj.bjc.6603756
- Elston CW, Ellis IO (2002). Pathological prognostic factors in breast cancer. i. the value of histological grade in breast cancer: experience from a large study with long-term followup. Histopathology, 41, 154-61. https://doi.org/10.1046/j.1365-2559.2002.14892.x
- Galea MH, Blamey RW, Elston CE, Ellis IO (1992). The nottingham prognostic index in primary breast cancer. Breast Cancer Res Treat, 22, 207-19. https://doi.org/10.1007/BF01840834
- Goldhirsch A, Winer EP, Coates AS (2013). Personalizing the treatment of women with early breast cancer: highlights of the st gallen international expert consensus on the primary therapy of early breast cancer. Ann Oncol, 24, 2206-23. https://doi.org/10.1093/annonc/mdt303
- Goldhirsch A, Wood WC, Coates AS, et al (2011). Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the st. gallen international expert consensus on the primary therapy of early breast cancer. Ann Oncol, 22, 1736-47. https://doi.org/10.1093/annonc/mdr304
- Jin SH, Kim SH, Kang BJ, et al (2014). Breast cancer recurrence according to molecular subtype. Asian Pac J Cancer Prev, 15, 5539-44. https://doi.org/10.7314/APJCP.2014.15.14.5539
- Khokher S, Qureshi MU, Mahmood S, Nagi AH (2013). Association of immunohistochemically defined molecular subtypes with clinical response to presurgical chemotherapy in patients with advanced breast cancer. Asian Pac J Cancer Prev, 14, 3223-28. https://doi.org/10.7314/APJCP.2013.14.5.3223
- Kilickap S, Kaya Y, Yucel B, et al (2014). Higher ki67 expression is associated with unfavorable prognostic factors and shorter survival in breast cancer. Asian Pac J Cancer Prev, 15, 1381-85. https://doi.org/10.7314/APJCP.2014.15.3.1381
- Kumaki N, Umemura S, Tang X, et al (2011). Alteration of immunohistochemical biomarkers between pre-and postchemotherapy: hormone receptors, HER2 and Ki-67. Breast Cancer, 18, 98-102. https://doi.org/10.1007/s12282-010-0238-1
- Paik S, Shak S, Tang G, et al (2004). A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New England J Med, 351.
- Pathmanathan N, Balleine RL (2013). Ki67 and proliferation in breast cancer. J Clin Pathol, 66, 512-16. https://doi.org/10.1136/jclinpath-2012-201085
- Reis-Filho J, Pusztai L (2011). Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet, 378, 1812-23. https://doi.org/10.1016/S0140-6736(11)61539-0
- Rinat Y, Woods R, Ravdin PM, Hayes MM, Gelmon KA (2010). Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol, 11, 174-83. https://doi.org/10.1016/S1470-2045(09)70262-1
- Saroona H, Hashmi AA, Khurshid A, et al (2013). Ki67 index in breast cancer: correlation with other prognostic markers and potential in Pakistani patients. Asian Pac J Cancer Prev, 14, 4353-58. https://doi.org/10.7314/APJCP.2013.14.7.4353
- Stumpp J, Dietl J, Simon W, Geppert M (1992). Growth fraction in breast carcinoma determined by Ki-67 immunostaining: correlation with pathological and clinical variables. Gynecol Obstet Invest, 33, 47-50. https://doi.org/10.1159/000294846
- Gong T, Shak S, Paik S, et al (2011). Comparison of the prognostic and predictive utilities of the 21-gene recurrence score assay and adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20. Breast Cancer Res Treat, 127, 133-42. https://doi.org/10.1007/s10549-010-1331-z
- Tanriverdi O, Meydan N, Barutca S (2014). Reconsideration of clinical and histopathological prognostic factors in breast cancer patients: A single center experience. Asian Pac J Cancer Prev, 15, 807-12. https://doi.org/10.7314/APJCP.2014.15.2.807
- The Cancer Genome Atlas Research Network (2012). Comprehensive molecular portraits of human breast tumours. Nature, 490, 61-70. https://doi.org/10.1038/nature11412
- Viale Giuseppe, Anita Giobbie-Hurder, Meredith M Regan, et al (2008). Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from breast international group trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol, 26, 5569-75. https://doi.org/10.1200/JCO.2008.17.0829
- Yoo C, Ahn J-H, Jung KH, et al (2012). Impact of immunohistochemistry-based molecular subtype on chemosensitivity and survival in patients with breast cancer following neoadjuvant chemotherapy. J Breast Cancer, 15, 203-10. https://doi.org/10.4048/jbc.2012.15.2.203
피인용 문헌
- Conserved genes and pathways in primary human fibroblast strains undergoing replicative and radiation induced senescence vol.49, pp.1, 2016, https://doi.org/10.1186/s40659-016-0095-2
- Prognostic parameters of luminal A and luminal B intrinsic breast cancer subtypes of Pakistani patients vol.16, pp.1, 2018, https://doi.org/10.1186/s12957-017-1299-9
- Predictive value of primary tumor parameters using 18F-FDG PET/CT for occult lymph node metastasis in breast cancer with clinically negative axillary lymph node vol.32, pp.9, 2018, https://doi.org/10.1007/s12149-018-1288-2